Amalgamated Bank Has $7.17 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Amalgamated Bank decreased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 5.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 52,071 shares of the company’s stock after selling 3,098 shares during the period. Amalgamated Bank owned 0.05% of Neurocrine Biosciences worth $7,169,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. RFP Financial Group LLC lifted its position in Neurocrine Biosciences by 346.5% during the 1st quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock worth $26,000 after buying an additional 149 shares in the last quarter. Mather Group LLC. acquired a new position in Neurocrine Biosciences during the 1st quarter worth about $26,000. Ashton Thomas Private Wealth LLC acquired a new position in Neurocrine Biosciences during the 2nd quarter worth about $28,000. Innealta Capital LLC acquired a new position in Neurocrine Biosciences during the 2nd quarter worth about $30,000. Finally, New Covenant Trust Company N.A. acquired a new position in Neurocrine Biosciences during the 1st quarter worth about $32,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analyst Upgrades and Downgrades

NBIX has been the topic of several research reports. JPMorgan Chase & Co. upped their price target on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Oppenheimer upped their target price on shares of Neurocrine Biosciences from $216.00 to $219.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. BMO Capital Markets cut their target price on shares of Neurocrine Biosciences from $142.00 to $128.00 and set a “market perform” rating on the stock in a research report on Thursday, August 29th. Wedbush restated an “outperform” rating and set a $152.00 target price on shares of Neurocrine Biosciences in a research report on Wednesday, May 29th. Finally, Piper Sandler upgraded shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and upped their target price for the company from $131.00 to $159.00 in a research report on Thursday, August 29th. Five analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $162.20.

Insider Buying and Selling

In related news, Director William H. Rastetter sold 14,250 shares of the stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the completion of the sale, the director now directly owns 37,491 shares of the company’s stock, valued at approximately $5,499,554.79. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, Director Gary A. Lyons sold 11,570 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $150.43, for a total transaction of $1,740,475.10. Following the completion of the transaction, the director now directly owns 119,047 shares of the company’s stock, valued at approximately $17,908,240.21. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William H. Rastetter sold 14,250 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the transaction, the director now directly owns 37,491 shares of the company’s stock, valued at $5,499,554.79. The disclosure for this sale can be found here. In the last three months, insiders sold 71,798 shares of company stock valued at $10,676,096. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences Stock Performance

NASDAQ NBIX opened at $120.46 on Friday. The business has a 50 day simple moving average of $139.07 and a 200 day simple moving average of $138.24. Neurocrine Biosciences, Inc. has a 52-week low of $103.63 and a 52-week high of $157.98. The stock has a market cap of $12.12 billion, a price-to-earnings ratio of 33.18 and a beta of 0.37.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Thursday, August 1st. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.52). Neurocrine Biosciences had a return on equity of 14.86% and a net margin of 16.00%. The business had revenue of $590.20 million for the quarter, compared to the consensus estimate of $545.98 million. During the same period in the previous year, the company posted $0.95 earnings per share. Neurocrine Biosciences’s revenue for the quarter was up 30.4% compared to the same quarter last year. On average, analysts predict that Neurocrine Biosciences, Inc. will post 4.19 EPS for the current year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.